Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Private investor base

Part of the apparent paradox stems from the industry s awkward position on the spectrum from publicly owned enterprise and pure private, investor-owned, and profit-driven enterprise. On the one hand, the pharmaceutical companies are structured as profit-seeking enterprises. Unlike many other profit-seeking industries, however, the research-based pharmaceutical industry cannot survive without government protection. [Pg.26]

Exhibit 6.14 shows the breakdown of the two broad categories, and emphasizes the shrinkage of the classic Eurodollar sector. This mirrors the relative decline of the private client part of the investor base. Private clients have traditionally been big buyers of Eurodollar bonds because of the popularity of the currency and the bearer nature of the obligations. The European tranches of dollar-denominated global bonds sold by US entities—who account for most of the origination in this regard— do not carry the same tax advantages. [Pg.195]

Surveys and interviews show that the attention paid to energy-efficiency investments in companies, public administrations and private households is often very low and heavily influenced by the priorities of those responsible for decision making (Ramesohl, 2000 Schmid, 2004 Stern, 1992). In other cases, project-based economic evaluations do not consider the relatively high transaction costs of the investor and also the substantial risks involved in the case of long-term investments both aspects may be decisive for small efficiency investments (Ostertag, 2003). [Pg.606]

Postmoney value is the market cap after the funding is complete and is what new investors focus on. Postmoney value is measured against other deals and the likely step-up in value prior to the next funding evenf. As the biotech market heats up or cools down, comparable values rise and fall. During the venture capital stage, investors try to estimate when the company can do an IPO (their exit strategy) and at what premoney value, and based on this estimate, coupled with their target rate of refum, they discount back to what would be a reasonable private postmoney value. [Pg.596]


See other pages where Private investor base is mentioned: [Pg.69]    [Pg.417]    [Pg.2]    [Pg.5]    [Pg.194]    [Pg.170]    [Pg.171]    [Pg.275]    [Pg.5]    [Pg.719]    [Pg.22]    [Pg.41]    [Pg.599]    [Pg.136]    [Pg.54]    [Pg.76]    [Pg.15]    [Pg.3]    [Pg.165]    [Pg.234]    [Pg.167]    [Pg.33]    [Pg.767]    [Pg.102]    [Pg.545]    [Pg.1271]    [Pg.1639]    [Pg.11]    [Pg.68]    [Pg.71]    [Pg.72]    [Pg.306]   
See also in sourсe #XX -- [ Pg.417 ]




SEARCH



Private

Privatization

© 2024 chempedia.info